CVS slides over 3% as bearish momentum persists amid split plans and regulatory concerns
CVS Health Corp (CVS) fell 3.4% after the company's plan to split into two independent publicly traded entities weighed on investor sentiment. The move is supported by pronounced technical weakness, with the stock remaining below major moving averages and immediate resistance levels.
Highlights
- CVS Health confirmed it will split into two publicly traded companies and restart share repurchases next quarter.
- A proposed CMS rule could impose stricter Medicare Advantage audits and impact the Aetna insurance segment.
- Shares of CVS Health trade below major moving averages with strong bearish momentum and a projected range of $79.87 to $85.91 over five days.
Ongoing selling as split news and regulatory risks strain sentiment
CVS Health recently announced plans to split into two independent publicly traded companies, a move that followed its November 4 disclosure and contributed to ongoing selling in the shares. Investor sentiment was further affected by a proposed CMS rule for stricter Medicare Advantage audits, which could impact the Aetna insurance business. CVS has also maintained its dividend at the same level for 12 consecutive quarters while prioritizing share buybacks and the upcoming corporate split. Plans to restart repurchases in the next quarter were confirmed, though price action has remained under broader selling pressure.
Broad momentum loss confirmed by bearish signals and weak support
CVS is trading below the 20-, 50-, and 200-day moving averages ($88.90, $89.29, and $89.29), highlighting persistent downward momentum across all timeframes. The nearest resistance is at $84.67, with immediate support at $82.67. Momentum remains firmly bearish, as signaled by a strong sell from MACD and weak trend strength on the ADX. Oscillators like RSI, Stochastic RSI, and CCI are neutral, indicating a lack of overbought or oversold conditions. Bearish pressure is dominant intraday, with negative BBP and the stock trading near session lows. Volatility is elevated at 3.71%, reinforcing the downside bias.
Previously it was reported that CVS Health was contending with technical resistance and sustained selling pressure despite long-term initiatives in innovation and healthcare delivery. The current article strengthens that assessment, as heightened volatility and negative momentum reinforce the importance of monitoring $79.87 as a key support level for potential further downside risk.